Search

A researcher from B J Medical College in Gujarat, India, has published new studies on Subcutaneous Panniculitis-like T-cell Lymphoma, a rare cutaneous T-cell lymphoma that resembles panniculitis. The research highlights the characteristics of this lymphoma, including subcutaneous nodules and plaques, and emphasizes the importance of histopathology and immunohistochemistry in diagnosis. This study provides valuable insights into the diagnosis and management of this rare form of T-cell lymphoma. [Extracted from the article]

Researchers at the University of Turin have published a study on new and emerging therapies in cutaneous T-cell lymphoma, focusing on Mycosis Fungoides as the most common form of the disease. The study highlights traditional and advanced treatment options, including immune modifiers, chemotherapeutic agents, and total skin irradiation. The research emphasizes recent advancements in therapeutic strategies for patients with cutaneous T-cell lymphoma. [Extracted from the article]

Researchers at Complutense University in Madrid, Spain, conducted a study on the health-related quality of life in patients with cutaneous T-cell lymphoma, specifically mycosis fungoides and Sezary syndrome. The study found that these conditions can significantly impact patients' quality of life, with symptoms affecting various domains such as emotions, functioning, and wellbeing. The research suggests that treatment decisions should consider individual patients' disease burden to improve their quality of life. [Extracted from the article]

A recent study conducted at City of Hope National Medical Center in Duarte, California, focused on the tumor microenvironment as a therapeutic target in Cutaneous T-Cell Lymphoma (CTCL). The research highlighted the role of malignant T cells in shaping the microenvironment to promote tumor progression and discussed strategies to target the tumor microenvironment for improved treatment efficacy. Funders for this research included the National Institutes of Health (NIH), the National Cancer Institute (NCI), and The Leukemia And Lymphoma Society Clinical Scholar Award. The study emphasized the importance of understanding the complex disease mechanisms and clinical outcomes in managing CTCL. [Extracted from the article]

A recent report from the University of Florida discusses the challenges in diagnosing mycosis fungoides (MF), the most common form of cutaneous T-cell lymphoma (CTCL). The researchers used next-generation sequencing (NGS) to identify pathogenic variants in 10 MF cases, revealing eight novel mutations in genes associated with MF. The study suggests that NGS can enhance the diagnosis of MF by detecting pathogenic variants that favor a neoplastic diagnosis over an inflammatory diagnosis. Further research in this area may lead to the discovery of therapeutic targets. [Extracted from the article]

A 71-year-old man developed cutaneous T-cell lymphoma following COVID-19 immunization with tozinameran. The man had a history of hypertension and diabetes and presented with altered mental status and acute skin issues after receiving the Pfizer COVID-19 vaccine. Despite treatments, his condition worsened, leading to sepsis and ultimately, his death. The skin biopsy revealed primary cutaneous gamma-delta T cell lymphoma, with the vaccine being identified as the likely cause. [Extracted from the article]

A recent study conducted at Henri Mondor University Hospital in Creteil, France, has found that pustular mycosis fungoides (MF) has a poor prognosis and is associated with shorter overall survival. The study compared the clinicopathological characteristics and outcomes of patients with pustular MF (pMF) to those with nonpustular MF (NpMF). The results showed that patients with pMF had more advanced-stage disease and a higher risk of large cell transformation (LCT) at diagnosis. The presence of histological pustules at diagnosis was associated with shorter overall survival and a higher cumulative incidence of LCT. The researchers recommend that pustules found on histology should be mentioned in MF pathology reports to prompt closer follow-up. [Extracted from the article]

A patent application has been submitted for the approval of a method to treat MYD88-mutant B-cell lymphomas. These lymphomas are characterized by mutations in the MYD88 gene and are associated with poorer response to chemotherapy. The method involves administering a compound called Compound A, which combines the activity of IRAK4 degradation and immunomodulatory imide drugs (IMiDs), to target the pathways involved in lymphoma development. The compound can be administered orally or intravenously, and different dosing schedules are suggested. The method can be used in combination with kinase inhibitors, BCL-2 inhibitors, or antibodies to enhance its effectiveness. [Extracted from the article]

Soligenix, Inc. has announced a partnership with Sterling Pharma Solutions to develop a commercially viable production technology for synthetic hypericin, the active ingredient in their drug products HyBryte and SGX302. These products are being developed to treat cutaneous T-cell lymphoma and psoriasis. The companies are working together to transfer and optimize manufacturing processes for clinical trials, with the goal of establishing a long-term commercial manufacturing collaboration. Soligenix aims to scale up production and reduce costs, while Sterling Pharma Solutions brings expertise in active pharmaceutical ingredient manufacturing and testing. [Extracted from the article]

Fenwal Inc. has been issued a patent for systems and methods for treating a biological fluid with light in the event of a bulb outage. The patent describes an irradiation device that is used in the treatment of biological fluids, such as blood and blood products, with photochemical agents for the inactivation of viruses, bacteria, and other contaminants. The device includes an array of multiple light sources and sensors to measure the intensity of light being delivered to the cells. In the event of a bulb outage, the device is designed to continue the photoactivation procedure by adjusting the duration of the light treatment or the intensity of the light emitted by the remaining light sources. [Extracted from the article]

A new report from Ohio State University discusses the rarity of CD20 expression in mycosis fungoides (MF), a type of cutaneous lymphoma. While CD20 expression is typically scarce in MF, isolated instances of CD20-positive MF have been documented infrequently. The report presents a unique case of CD20-positive MF in a 30-year-old man and emphasizes the need for further investigation and documentation of similar cases to understand the clinical features, prognosis, and optimal therapeutic strategies. The long-term prognosis and outcomes in patients with hypopigmented MF and CD20 positivity remain unclear, highlighting the necessity for continued research. [Extracted from the article]

A study conducted at the Fred Hutchinson Cancer Research Center in Seattle, Washington, focused on the impact of mycosis fungoides (MF)/Sézary Syndrome (SS) on the health-related quality of life (HRQoL) of patients. The researchers developed a new subscale called CTCL-S, which is part of the Functional Assessment of Cancer Therapy-General (FACT-G) instrument, to assess HRQoL in patients with MF/SS. The study found that the CTCL-S instrument demonstrated high reproducibility and good performance in assessing HRQoL in this patient population. The findings support the use of the FACT-CTCL instrument as a disease-specific tool for evaluating HRQoL in patients with MF/SS. [Extracted from the article]

A recent study conducted by researchers at Yale University School of Medicine in New Haven, Connecticut, explores the clinical and histologic variants of cutaneous T-cell lymphoma (CTCL) that manifest with CD8+ T-cell differentiation. The study emphasizes the importance of utilizing clinical, histologic, and immunohistochemical findings to accurately diagnose and develop appropriate treatment plans for these rare diseases. The researchers highlight several CTCL subtypes that can demonstrate CD8 positivity, each with distinct clinical manifestations and treatment algorithms. This information is valuable for healthcare professionals in diagnosing and managing CTCL cases effectively. [Extracted from the article]

Cytomx Therapeutics Inc. has been granted a patent for activatable cytokine constructs, which aim to improve the effectiveness and reduce the side effects of cytokine therapy. Cytokines are small proteins that regulate immune responses, and while they have clinical benefits, they can also cause toxicities. The patent describes activatable cytokine constructs that can be activated in diseased tissue while minimizing their activity in healthy tissue, potentially reducing toxicity and increasing the therapeutic window. The patent includes claims for pharmaceutical compositions and polynucleotides encoding the constructs. The full patent can be accessed using the provided URL. [Extracted from the article]

Noile-Immune Biotech Inc. has submitted a patent application for a new immunocompetent cell and expression vector that can enhance immune function in cancer immunotherapy. The invention focuses on factors that regulate the immune function of these cells and introduces an expression vector to generate cells with improved immune effects. The patent aims to address the limitations of current immunotherapy treatments, particularly in the treatment of solid tumors. The invention targets specific cancer antigens and shows potential efficacy against various types of solid tumors. The patent application provides detailed sequences and variations of the receptor and the cell surface molecule. [Extracted from the article]

A report from Heidelberg University in Germany discusses research findings on Sezary Syndrome, a type of lymphoproliferative disorder. The study focuses on the diagnosis and treatment of the syndrome, which is characterized by cell death resistance. The researchers propose an integrated approach that considers the expression of specific markers on Sezary cells and their sensitivity to cell death. They found that different treatments in vitro were able to induce cell death in the malignant T cell populations, and after three months of treatment, the cell death sensitivity was restored. This novel approach could potentially lead to better therapy stratification for Sezary Syndrome. [Extracted from the article]

A recent study conducted by researchers at Thomas Jefferson University in Philadelphia has found that the use of the drug dupilumab for treating atopic dermatitis (AD) is associated with an increased risk of developing cutaneous T-cell lymphoma (CTCL). The study, which analyzed data from over 1 million patients, revealed that patients treated with dupilumab had a higher relative risk of developing CTCL compared to those who were not treated with the drug. The risk was highest within the first year of therapy and in adult patients. The findings suggest that caution should be exercised when using dupilumab in certain patient groups. [Extracted from the article]

A recent report discusses research findings on cutaneous T-cell lymphoma, a type of cancer that affects the skin. The study focuses on the combination of mogamulizumab, a humanized antibody, and low-dose total skin electron beam therapy (TSEBT) as a potential treatment option for advanced-stage mycosis fungoides and Sezary syndrome. The researchers found that this combination may lead to improved response times in the skin and blood within two weeks. However, further research is needed to determine the efficacy and tolerability of this treatment combination compared to monotherapy. [Extracted from the article]

A patent has been issued for a compound that specifically binds to KIR3DL2, a protein found on the surface of peripheral T cell lymphomas (PTCLs). The compound can be used in the treatment of PTCLs, particularly advanced and aggressive forms of the disease. By targeting KIR3DL2 with antibodies, the compound can potentially deplete PTCL cells and improve patient outcomes. This patent provides a potential new therapeutic option for patients with PTCL, a type of lymphoma that has a poor prognosis and limited treatment options. [Extracted from the article]

A recent study conducted by researchers at the Icahn School of Medicine at Mount Sinai has provided new insights into the molecular characteristics of different subtypes of cutaneous T-cell lymphoma (CTCL). The study utilized single-cell RNA sequencing to compare CD4(+), CD8(+), and TCR-gamma/delta(+) CTCL lesions. The findings revealed distinct molecular patterns associated with each subtype, which may aid in the development of targeted treatment approaches for CTCL. The research highlights the importance of understanding the specific molecular signatures of different CTCL subtypes to improve patient outcomes. [Extracted from the article]

A recent study conducted by researchers at the National Autonomous University of Mexico (UNAM) focuses on lymphomatoid papulosis (LyP), a type of cutaneous T-cell lymphoma. The study presents the case of a 22-year-old man with subacute dermatosis who was diagnosed with type D LyP. The researchers highlight the rarity of type D LyP in Latin-American patients and emphasize the importance of sharing these findings. The prognosis for LyP is generally good, with a 10-year survival rate of 100%. [Extracted from the article]

A clinical case report on mycosis fungoides, a form of T-cell lymphoma, was presented by researchers from the University of Miami. The report describes the case of a 64-year-old Hispanic male who presented with hardened, erythematous lesions on his trunk and upper extremities. Despite initial treatment with topical glucocorticoids and systemic retinoids, the disease progressed and involved lymph nodes, requiring aggressive chemotherapy. The report highlights the aggressive and resistant nature of mycosis fungoides in this particular case, leading to a poor prognosis. [Extracted from the article]

A recent report from the Fred Hutchinson Cancer Research Center in Seattle, Washington explores the immunological responses to immunotherapies in patients with Cutaneous T-Cell Lymphoma (CTCL). CTCL is a type of skin cancer with limited treatment options and poor survival rates. The study found that neoplastic T cells did not show signs of activation after immunotherapy, while interferon-gamma (IFN-g) induced muted endogenous immunological responses and anti-PD-1 therapy elicited broader changes. The research provides insights into the effects of immunotherapy in CTCL patients and offers a framework for multi-omic analysis of clinical trials. [Extracted from the article]

A report from Columbia University discusses the research on cutaneous T-cell lymphoma (CTCL) and its etiology. The researchers have explored the links between CTCL and environmental chemical exposures, such as pesticides and benzene, as well as infectious factors like viruses and bacteria. The review synthesizes studies on these exposures, the aryl hydrocarbon receptor, and the involvement of pathogens in CTCL development, providing insight into the pathogenesis of the disease. The research has been peer-reviewed and published in the Journal of Investigative Dermatology. [Extracted from the article]

This article discusses a clinical trial, NCT06585124, that aims to investigate the relationship between T cell activation and the occurrence of hemophagocytic lymphohistiocytosis (HLH) in patients with newly diagnosed lymphomas. The trial will involve 150 patients with aggressive lymphoma, and their peripheral blood samples will be analyzed using flow cytometry to assess T-lymphocyte activation. The results will be compared with diagnostic scores to determine their effectiveness in diagnosing lymphoma-associated HLH (LA-HLH). The study aims to improve early diagnosis and management of secondary HLH, particularly in cases associated with lymphoma. The trial is currently recruiting participants and is expected to be completed by May 2026. [Extracted from the article]

A patent application has been submitted for a combination therapy involving an LXR agonist and an inhibitor compound. The LXR receptor is known to regulate lipid homeostasis and has potential therapeutic applications for various diseases, including cancer and Alzheimer's. However, LXR agonists have shown side effects, such as increased triglyceride levels. The inventors propose using an inhibitor compound to attenuate or eliminate these side effects. The patent application includes methods of combination therapy, pharmaceutical compositions, and specific criteria for the agonists and inhibitors. [Extracted from the article]

A recent study conducted at Sichuan University in China explored the role of exosomes derived from EBV-positive B cells in promoting immune evasion in EBV-associated T/NK-cell lymphoproliferative diseases (EBV-T/NK-LPDs). The researchers hypothesized that these exosomes could stimulate the development of EBV-T/NK-LPDs by activating the STAT3/IL-10/PD-L1 pathway, which is associated with an immunosuppressive microenvironment. The study found that exosomes derived from EBV-positive B cells significantly activated this pathway and induced the overexpression of IL-10/PD-L1 in CTCL cells. The findings provide new insights into the mechanisms of immune evasion in EBV-T/NK-LPDs. [Extracted from the article]

Researchers at the University of Cantabria in Spain have conducted a study on cutaneous T-cell lymphoma (CTCL), a type of cancer characterized by high relapse rates and a lack of curative treatments. The study focuses on the potential of kinase inhibitors as therapeutic options for CTCL. The researchers highlight the JAK/STAT, MAPK/ERK, PI3K/Akt, and NF-kB signaling pathways as targets for inhibition. While JAK inhibitors show promise, further studies, particularly clinical trials, are needed to assess their benefits and potential adverse events, especially in patients with immunosuppression or underlying autoimmune diseases. [Extracted from the article]

Researchers from the University Medical Centre Mainz have published a study on cutaneous T-cell lymphoma (CTCL), specifically focusing on mycosis fungoides (MF), the most common form of CTCL. The study aimed to understand the role of the skin microbiome in MF development and progression. Through their research, the scientists identified a subgroup of MF patients with dysbiosis on MF lesions and an overgrowth of Staphylococcus aureus (S. aureus) on plaque-staged lesions. This dysbiosis and S. aureus outgrowth were associated with lower event-free survival and a restricted T cell receptor repertoire. The findings suggest the potential for microbiome-modulating treatments targeting S. aureus to prevent MF progression. [Extracted from the article]

A study conducted at the University of Texas Southwestern Medical Center compared two different T-cell receptor-g clonality assays for diagnosing mycosis fungoides, a type of cutaneous lymphoma. The researchers found that the accuracy of the two-tube assay was slightly better than the one-tube assay, but the one-tube assay had better specificity. They also noted that changing assays on the same biopsy could result in a change of clonality interpretation, potentially affecting the diagnosis. This research provides new insights into the use of T-cell receptor assays for diagnosing mycosis fungoides. [Extracted from the article]

This article provides information about a newly launched clinical trial in China for a drug called YK012, which is being tested in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of YK012, and it is the first-in-human trial for this drug. The study will involve administering YK012 to patients through intravenous infusion every two weeks for a treatment cycle of four weeks. The primary outcome measures include assessing adverse events, dose-limiting toxicity, and determining the maximum tolerated dose for further clinical trials. The trial is currently recruiting participants, with a target enrollment of 48 individuals, and the primary investigator is Yuankai Shi from the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. [Extracted from the article]

A recent report from the University of Southern California highlights the disparities in cutaneous T-cell lymphoma (CTCL) among people of color (POC) compared to white individuals. While skin cancers are more common in white individuals, CTCL affects POC at higher rates. The report reviews the differences in epidemiology, clinical presentation, treatments, and outcomes of CTCL subtypes in Black, Asian or Pacific-Islander (API), and Hispanic patients. The findings suggest that there are nuances in the course of CTCL that differ with race, and prognostic factors also vary. The report emphasizes the need for physician awareness and knowledge of racial nuances in CTCL to address these disparities. [Extracted from the article]

A recent study conducted by researchers at Columbia University has found that a combination of two drugs, romidepsin and afatinib, shows promising results in treating cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas are a type of cancer that affects the skin-resident T-cells. While current treatments using histone deacetylase inhibitors are effective, they are not curative. The combination of romidepsin and afatinib was found to have strong synergistic antitumor effects by inhibiting Jak-signal transducer and activator of transcription signaling. This research suggests a potential new treatment option for cutaneous T-cell lymphomas. [Extracted from the article]

A case report from Airlangga University in Surabaya, Indonesia, discusses the successful treatment of a 64-year-old Indonesian woman with mycosis fungoides (MF), the most prevalent cutaneous T-cell lymphoma. The patient initially presented with itchy reddish skin and thick scales, and was misdiagnosed with psoriasis vulgaris (erythroderma) before a skin biopsy revealed MF. The patient was treated with a combination of CHOP chemotherapy, narrow band-UVB therapy, and symptomatic therapies, resulting in a favorable therapeutic response. The report emphasizes the importance of early diagnosis and treatment for better prognosis, as there is currently no cure for MF. [Extracted from the article]

The article discusses a Phase 1b/2a trial of duvelisib combined with romidepsin for relapsed or refractory T-cell lymphomas. Researchers at Memorial Sloan-Kettering Cancer Center found that the combination was more effective and had lower toxicity compared to duvelisib with bortezomib, suggesting it as a promising treatment option for T-cell lymphomas. Topics include the efficacy of combined PI3K and HDAC inhibition, safety profiles of treatments, and clinical response rates.

The article highlights a U.S. patent filed by inventors at Tel-Aviv University Ltd. in Israel for targeted lipid-based nanoparticles designed for the efficient delivery of RNAi molecules, such as siRNA, to leukocytes, specifically B-cells and T-cells, for the treatment of diseases like lymphoma, leukemia, and multiple myeloma. It explains how these nanoparticles, functionalized with antibodies like anti-CD4 and anti-CD38, enable precise gene silencing in difficult-to-transfect immune cells.

A new report discusses the dermatological manifestations of HIV/AIDS and their implications for esthetic and clinical management. The review explores various skin conditions associated with HIV, including both HIV-specific dermatoses and common dermatoses. It also covers skin infections, HIV-related malignancies, antiretroviral therapy-related skin changes, immune reconstitution inflammatory syndrome, ectoparasitic infestations, and skin complications arising from intravenous drug use. The review emphasizes the importance of early recognition and appropriate treatment strategies for better patient outcomes and enhanced quality of life. It also highlights the multidisciplinary approach needed to manage the diverse and complex skin conditions associated with HIV. [Extracted from the article]

A recent study conducted by researchers from Loma Linda University in California examined the association between the use of the drug dupilumab and the development of cutaneous T-cell lymphoma (CTCL). The study found that CTCL was diagnosed, on average, 7.8 months after the initiation of dupilumab treatment. Biopsies conducted after dupilumab use revealed a greater density of cells and a predominant lichenoid pattern compared to pre-dupilumab biopsies. The researchers suggest that earlier biopsies, three to four months after starting dupilumab, may aid in the earlier recognition of CTCL in patients who are not improving or experiencing morphologic changes on the drug. [Extracted from the article]

This document provides information about a clinical trial, NCT06561425, that is currently recruiting participants to evaluate the feasibility, safety, and efficacy of an experimental treatment called GLPG5101 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). The trial aims to determine the optimal dose of GLPG5101 with the fewest side effects in the first phase, and in the second phase, all participants will receive the best dose identified. The trial will assess various outcome measures, including adverse events, objective response, duration of response, and survival rates. The trial is open to individuals with aggressive DLBCL, FL, MZL, MCL, BL, PCNSL, relapsed or refractory disease, and adequate bone marrow, renal, hepatic, and pulmonary function. The trial is being conducted in the United States, Belgium, and the Netherlands, and contact information for further inquiries is provided. [Extracted from the article]

Valcuria AB, a company based in Lund, Sweden, has been issued a patent for a composition and method for pretreating cancer. The patent describes the use of a histone deacetylase (HDAC) inhibitor, specifically valproic acid, in combination with steroids as a pretreatment for cancer. The invention focuses on the administration of the HDAC inhibitor in both immediate release and extended release forms to achieve a desired plasma concentration quickly and maintain it for at least 48 hours. This approach aims to enhance the effectiveness of cancer treatment and minimize side effects. The patent provides details on the pharmaceutical composition, a device, and a kit for administering the HDAC inhibitor. The method can be used in combination with chemotherapy or immunotherapy for various types of cancer, including lymphomas and myeloma. [Extracted from the article]

A study conducted at Nanjing University in China evaluated the efficacy and safety of the mSMILE chemotherapy regimen in treating Epstein-Barr virus-associated natural killer (NK) and T-cell lymphoma. The study included eight patients, and the results showed that 62.5% achieved complete remission and 87.5% had an overall response rate. The most common adverse reactions were hematologic toxicities and nonhematologic adverse reactions, which were resolved with anti-infective therapy. The researchers concluded that mSMILE appears to be a safe and effective treatment option for this type of lymphoma and should be further investigated in clinical trials. [Extracted from the article]

A study conducted by New York University (NYU) provides new insights into folliculitis, specifically eosinophilic pustular folliculitis, in an HIV-positive 63-year-old male. The patient presented with fever, cough, altered mental status, and a skin eruption characterized by flesh-colored and erythematous follicular papules on the face, neck, and chest. The differential diagnoses included various skin conditions and malignancies. A skin punch biopsy confirmed the diagnosis of eosinophilic pustular folliculitis. This research has been peer-reviewed and published in The American Journal of Medicine. [Extracted from the article]

The article focuses on a Phase 2, open-label, randomized clinical trial evaluating the combination of pirtobrutinib and brexucabtagene autoleucel in patients with relapsed or refractory mantle cell lymphoma. Topics include the study design and goals, which involve assessing progression-free survival and comparing the efficacy and safety of concurrent pirtobrutinib versus no concurrent pirtobrutinib, as well as the secondary outcomes related to severe adverse events and overall response rates.

The article offers information on a case of primary cutaneous anaplastic large-cell lymphoma (C-ALCL) and its clinical presentation. Topics discussed include the disease's characteristic solitary papules or nodules; the diagnostic process involving biopsy and immunohistochemical profiling; and also mentions about the treatment and recurrence of the condition.

The article offers information on an atypical case of mycosis fungoides with a rare phenotype and SOCS1 mutation. Topics discussed include the diagnostic challenges due to similarities with benign skin disorders; the unique blastic morphology and cytotoxic phenotype of the T-cell lymphoma; and the identification of a likely pathogenic SOCS1 mutation and STAT3 variant through next-generation sequencing.

A recent report from Tishreen University provides a comprehensive review of mycosis fungoides (MF), the most common type of primary cutaneous T-cell lymphoma. MF is known for its wide range of clinical manifestations that can mimic various skin disorders, making diagnosis challenging. The study focuses on the different clinical and histopathological variants of MF and their differential diagnoses. The research emphasizes the importance of recognizing these variants to improve prognosis and timely treatment. For more information, readers can contact Jacob Al-Dabbagh at Tishreen University. [Extracted from the article]

A recent report from researchers at Centro Hospitalar Universitario de Lisboa Central in Lisbon, Portugal, discusses the trichoscopic findings in folliculotropic mycosis fungoides (FMF), a type of cutaneous lymphoma. The report focuses on a case study of a 50-year-old man with FMF stage IB, describing the clinical findings and trichoscopic evaluation of his condition. The researchers suggest that trichoscopic evaluation could be useful in guiding differential diagnosis and identifying early disease. This information may be valuable for individuals conducting research on mycosis fungoides and related dermatological conditions. [Extracted from the article]

This document provides information on a clinical trial (NCT06536049) that is investigating the use of a combination therapy for the treatment of aggressive B-cell non-Hodgkin lymphoma. The trial involves the use of epcoritamab, a bispecific antibody, and ibrutinib, a Bruton's tyrosine kinase inhibitor. The goal of the trial is to determine the optimal dose, safety, and efficacy of this combination therapy. The trial is being conducted by the Ohio State University Comprehensive Cancer Center in collaboration with AbbVie and Genmab. [Extracted from the article]